HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

552.942

-21.885-3.81%

Number of Gainers:2

Number of Losers:30

Number of Flat:2

PE:- -

High:575.370

Open:574.827

Low:552.568

Close:574.827

Volume:38.76M

Turnover:778.14M

Market Cap:344.78B

Float Cap:309.41B

Loading ...

CStone Pharmaceuticals-B Shares Climb Over 5% Following UK Regulatory Approval for Sugemalimab's New Lung Cancer Indication

Domestic Innovative Drug BD Transaction Value Ranks First Globally, This ETF Secures Early Position

Medical Device Firms Emerge as Key Players in A-Share Market

Ascentage Pharma to Participate in Three Upcoming Investor Conferences

EDDING GENOR (06998) Allocates HK$1.461 Million for Share Buyback on February 23

Edding Genor Group Holdings files HKEX next-day disclosure return reporting 457,500-share repurchase at HKD 3.19343 per share

BUZZ-HK-listed HBM jumps on licensing deal with Solstice on oncology drug

HBM HOLDINGS-B Shares Surge Over 8% in Morning Session on Major Global Licensing Deal for Next-Generation Antibody

CStone Pharma-B's PD-L1 Antibody Sugemalimab Gains UK Approval for Advanced Lung Cancer

HBM HOLDINGS-B Enters Exclusive Licensing and Equity Partnership for HBM4003 with Solstice Oncology

CStone Pharmaceuticals - Sugemalimab Receives UK Mhra Approval for Stage Iii Nsclc

THOMSON REUTERS

UK MHRA approves CStone’s sugemalimab for unresectable stage III NSCLC

HBM Holdings inks licensing and equity partnership deal with Solstice Oncology for HBM4003

Hbm Holdings - License Agreement and Equity Partnership Agreement With Solstice Oncology for Hbm4003

THOMSON REUTERS

Hbm Holdings - Co to GET Upfront Consideration Valued at Over US$105 Mln

THOMSON REUTERS

Hbm Holdings - Eligible to Receive Additional Development, Regulatory and Commercial Milestone Payments of up to US$1.1 Bln

THOMSON REUTERS

Pharmaceutical Supply Chain Momentum Strengthens: Sinolink Securities Highlights Dual Investment Themes in CXO Sector

EDDING GENOR Spends HK$44,100 on Share Buyback

EDDING GENOR (06998) Allocates HK$44,100 for Share Buyback on February 20

Edding Genor Group Holdings Files HKEX Next Day Disclosure Return on 14,000-Share Repurchase at HK$3.15107 Each

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":552.94165,"timestamp":1771905597868,"preClose":574.827,"halted":0,"volume":38757645,"delay":0,"changeRate":-0.038073,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Noon Closed","change":-21.885376,"latestTime":"02-24 12:00:00","open":574.827,"high":575.3701,"low":552.56757,"amount":778136328,"amplitude":0.039669,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771909200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1771896600000,1771905600000],[1771909200000,1771920000000]],"pbRate":5.026953,"peRate":-40.55114,"turnoverRate":0.001482,"increases":2,"decrements":30,"flats":0,"marketCap":344775161120,"floatMarketCap":309414919216},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":575.3701,"amplitude":0.039669,"preClose":574.827,"low":552.56757,"pbRate":"5.026953","latestPrice":552.94165,"volume":38757645,"delay":0,"open":574.827,"prevYearClose":556.26263,"prevWeekClose":571.129,"prevMonthClose":555.241,"prevQuarterClose":556.263,"fiveDayClose":551.442,"twentyDayClose":569.48,"sixtyDayClose":594.047,"secType":"PLATE","market":"HK","turnoverRate":0.001482,"peRate":-40.55114,"marketCap":344775161120,"floatMarketCap":309414919216,"timestamp":1771905597868,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":2,"down":30,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1161661386","title":"CStone Pharmaceuticals-B Shares Climb Over 5% Following UK Regulatory Approval for Sugemalimab's New Lung Cancer Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1161661386","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161661386?lang=en_us&edition=fundamental","pubTime":"2026-02-24 10:36","pubTimestamp":1771900611,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals-B (02616) rose more than 5% in Hong Kong trading. At the time of writing, the stock was up 5.12% to HK$6.36, with a turnover of HK$23.93 million. The increase follows the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK4585","BK4588","BK4134","BK1574","VT","02616","BK1161","III"],"gpt_icon":0},{"id":"1147442940","title":"Domestic Innovative Drug BD Transaction Value Ranks First Globally, This ETF Secures Early Position","url":"https://stock-news.laohu8.com/highlight/detail?id=1147442940","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147442940?lang=en_us&edition=fundamental","pubTime":"2026-02-24 08:51","pubTimestamp":1771894296,"startTime":"0","endTime":"0","summary":"In recent years, the biotechnology industry has entered a phase of rapid growth, becoming a key sector driving global technological revolution and industrial transformation, continuously attracting...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","06978","BK1161","BK4550","BK1574","BK4588","BK4585","FDN"],"gpt_icon":0},{"id":"1127447506","title":"Medical Device Firms Emerge as Key Players in A-Share Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1127447506","media":"Deep News","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127447506?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:52","pubTimestamp":1771887138,"startTime":"0","endTime":"0","summary":"This year, the A-share market has welcomed 16 new listings, with medical device companies accounting for four of them, marking a notable highlight in the IPO market at the start of the year. Among...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159883","BK1583","09997","399300","BK1222","BK1574","BK1100","09996","159982"],"gpt_icon":0},{"id":"2613784767","title":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2613784767","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613784767?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:00","pubTimestamp":1771851652,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL8237Kb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014039.USD","SG9999014013.SGD","BK4112","SG9999014021.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210150020.SGD","BK1161","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","SG9999014005.SGD","LU2210149790.SGD","BK4588","06855","BK1574","NDAQ"],"gpt_icon":0},{"id":"1182045646","title":"EDDING GENOR (06998) Allocates HK$1.461 Million for Share Buyback on February 23","url":"https://stock-news.laohu8.com/highlight/detail?id=1182045646","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182045646?lang=en_us&edition=fundamental","pubTime":"2026-02-23 19:00","pubTimestamp":1771844413,"startTime":"0","endTime":"0","summary":"EDDING GENOR (06998) announced that on February 23, 2026, the company repurchased 457,500 shares at a total cost of HK$1.461 million. The buyback price ranged from HK$3.17 to HK$3.20 per share.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06998","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2613785731","title":"Edding Genor Group Holdings files HKEX next-day disclosure return reporting 457,500-share repurchase at HKD 3.19343 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2613785731","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613785731?lang=en_us&edition=fundamental","pubTime":"2026-02-23 18:53","pubTimestamp":1771844018,"startTime":"0","endTime":"0","summary":"Edding Genor Group Holdings files HKEX next-day disclosure return reporting 457,500-share repurchase at HKD 3.19343 per share. Edding Genor Group Holdings Ltd.  filed a next day disclosure return with HKEX reporting that it repurchased 457,500 ordinary shares on 23 February 2026 to be held as treasury shares. The shares were bought on-market at a volume-weighted average price of about HK$3.19 per share , for an aggregate consideration of HK$1,460,995.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 23, 2026, and is solely responsible for the infor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL7W75mv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","06998","BK1583"],"gpt_icon":0},{"id":"2613440208","title":"BUZZ-HK-listed HBM jumps on licensing deal with Solstice on oncology drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2613440208","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613440208?lang=en_us&edition=fundamental","pubTime":"2026-02-23 10:22","pubTimestamp":1771813359,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed HBM jumps on licensing deal with Solstice on oncology drug ** Shares of HBM Holdings 2142.HK jump 9.3% to HK$13.38, their highest level since January 20, and on course for a third straight session of gains** Stock of the Chinese immuno-oncology and immunology diseases therapeutics developer on track for biggest one-day pct gain since August 29** HBM says it has agreed to grant Solstice Oncology - a clinical-stage biotechnology firm set up by venture capital investors, an exclusive license to develop and commercialise a clinical-stage portfolio asset for tumors treatment HBM4003  outside Greater China  ** HBM is eligible to receive upfront consideration valued at $105 million, comprising an upfront cash payment of $50 million, a near-term cash payment of $5 million, and over $50 million of equity interest in Solstice Oncology to be issued and allotted to the company** HBM is also eligible to receive regulatory and commercial milestone payments of up to $1.1 billion on the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL1N3ZJ014:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02142","BK1583","BK1161"],"gpt_icon":0},{"id":"1158828817","title":"HBM HOLDINGS-B Shares Surge Over 8% in Morning Session on Major Global Licensing Deal for Next-Generation Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1158828817","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158828817?lang=en_us&edition=fundamental","pubTime":"2026-02-23 09:50","pubTimestamp":1771811417,"startTime":"0","endTime":"0","summary":"HBM HOLDINGS-B (02142) saw its shares rise more than 8% during the morning trading session. At the time of writing, the stock was up 7.92%, trading at HK$13.21 with a turnover of HK$217.947 million....","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4585","02142","VXUS","VT","BK1583","BK1574","BK4588"],"gpt_icon":0},{"id":"1167405741","title":"CStone Pharma-B's PD-L1 Antibody Sugemalimab Gains UK Approval for Advanced Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1167405741","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167405741?lang=en_us&edition=fundamental","pubTime":"2026-02-23 08:20","pubTimestamp":1771806029,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals-B (02616) announced that its new indication application for sugemalimab has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The approval...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK1161","02616","BK4134","BK1574"],"gpt_icon":0},{"id":"1142228049","title":"HBM HOLDINGS-B Enters Exclusive Licensing and Equity Partnership for HBM4003 with Solstice Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=1142228049","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142228049?lang=en_us&edition=fundamental","pubTime":"2026-02-23 08:16","pubTimestamp":1771805818,"startTime":"0","endTime":"0","summary":"HBM HOLDINGS-B (02142) has announced the signing of an exclusive licensing agreement and an equity cooperation agreement with Solstice Oncology, a clinical-stage biotechnology company established by...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2613727222","title":"CStone Pharmaceuticals -  Sugemalimab Receives UK Mhra Approval for Stage Iii Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2613727222","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613727222?lang=en_us&edition=fundamental","pubTime":"2026-02-23 08:07","pubTimestamp":1771805234,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nFWN3ZI00J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2613272275","title":"UK MHRA approves CStone’s sugemalimab for unresectable stage III NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2613272275","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613272275?lang=en_us&edition=fundamental","pubTime":"2026-02-23 08:06","pubTimestamp":1771805215,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals said the UK Medicines and Healthcare products Regulatory Agency  has approved a new indication for sugemalimab as monotherapy for adult patients with unresectable stage III non-small cell lung cancer  with PD-L1 expression on at least 1% of tumor cells, without sensitising EGFR mutations or ALK/ROS1 genomic aberrations, whose disease has not progressed after platinum-based chemoradiotherapy. The company said the approval was based on results from the Phase III GEMSTONE-301 trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 23, 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL7T8KFm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"2613724152","title":"HBM Holdings inks licensing and equity partnership deal with Solstice Oncology for HBM4003","url":"https://stock-news.laohu8.com/highlight/detail?id=2613724152","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613724152?lang=en_us&edition=fundamental","pubTime":"2026-02-23 08:00","pubTimestamp":1771804849,"startTime":"0","endTime":"0","summary":"HBM Holdings Ltd. has entered into an exclusive license agreement and equity partnership with Solstice Oncology to develop and commercialize its clinical-stage asset HBM4003 outside Greater China. HBM said it is eligible to receive upfront consideration valued at over US$105 million, including US$55 million in cash and more than US$50 million in Solstice equity, plus up to about US$1.1 billion in milestones and tiered royalties on net sales outside Greater China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 23, 2026, and is solely responsible for the informat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL7nBBtv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2613724962","title":"Hbm Holdings - License Agreement and Equity Partnership Agreement With Solstice Oncology for Hbm4003","url":"https://stock-news.laohu8.com/highlight/detail?id=2613724962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613724962?lang=en_us&edition=fundamental","pubTime":"2026-02-23 08:00","pubTimestamp":1771804840,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nFWN3ZG0TW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"2613272499","title":"Hbm Holdings -  Co to GET Upfront Consideration Valued at Over US$105 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2613272499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613272499?lang=en_us&edition=fundamental","pubTime":"2026-02-23 08:00","pubTimestamp":1771804840,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nFWN3ZG0TW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","BK1583","02142"],"gpt_icon":0},{"id":"2613272479","title":"Hbm Holdings - Eligible to Receive Additional Development, Regulatory and Commercial Milestone Payments of up to US$1.1 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2613272479","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613272479?lang=en_us&edition=fundamental","pubTime":"2026-02-23 08:00","pubTimestamp":1771804840,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nFWN3ZG0TW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","02142","BK1583"],"gpt_icon":0},{"id":"1106648944","title":"Pharmaceutical Supply Chain Momentum Strengthens: Sinolink Securities Highlights Dual Investment Themes in CXO Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=1106648944","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106648944?lang=en_us&edition=fundamental","pubTime":"2026-02-22 19:28","pubTimestamp":1771759729,"startTime":"0","endTime":"0","summary":"Sinolink Securities has released a research report indicating a global recovery in pharmaceutical investment and financing in 2025, with the total amount reaching $192.1 billion in the first eleven...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","600109","BK1574","BK0276","BK1191","BK0183","CXO","BK0028","BK0188","BK0012","BK0201"],"gpt_icon":0},{"id":"1180547929","title":"EDDING GENOR Spends HK$44,100 on Share Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=1180547929","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180547929?lang=en_us&edition=fundamental","pubTime":"2026-02-22 13:10","pubTimestamp":1771737034,"startTime":"0","endTime":"0","summary":"EDDING GENOR (06998) announced that on February 20, 2026, the company repurchased 14,000 shares at a cost of HK$44,100. The repurchase price per share ranged between HK$3.15 and HK$3.16.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1583","06998"],"gpt_icon":0},{"id":"1126450927","title":"EDDING GENOR (06998) Allocates HK$44,100 for Share Buyback on February 20","url":"https://stock-news.laohu8.com/highlight/detail?id=1126450927","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126450927?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:36","pubTimestamp":1771590970,"startTime":"0","endTime":"0","summary":"On February 20, EDDING GENOR (06998) announced it repurchased 14,000 shares at a cost of HK$44,100. The buyback price per share ranged between HK$3.15 and HK$3.16.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK1574","06998"],"gpt_icon":0},{"id":"2612264536","title":"Edding Genor Group Holdings Files HKEX Next Day Disclosure Return on 14,000-Share Repurchase at HK$3.15107 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2612264536","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612264536?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:32","pubTimestamp":1771590734,"startTime":"0","endTime":"0","summary":"Edding Genor Group Holdings Ltd.  filed a next day disclosure return with HKEX reporting that it repurchased 14,000 ordinary shares on 20 February 2026 to be held as treasury shares. The buyback was conducted on the Exchange at prices between HKD 3.15 and HKD 3.16 per share , for an aggregate consideration of HKD 44,115.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edding Genor Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL8D8T7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","06998","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":113,"code":"91000000","status":"200"}]}}